Glioblastoma (GBM) – one of the most aggressive and invasive forms of brain cancer, which is highly resistant to anticancer drugs. Soohyun Hong et al. recently published findings that may provide new insights into a better understanding of GBM-immunity interaction and for the development of a novel therapeutic strategy for GBM. GBM constitutes a highly complicated and dynamic in vivo tumor-microenvironment (TME) that modulates and participates in GBM proliferation, invasion, and resistance to drugs. GBM progression is closely associated with microglia activation; therefore, understanding the regulation of the crosstalk between human GBM and microglia may help develop effective therapeutic strategies. It was shown that miR-124 microRNA is enriched in the normal brain, but its levels are downregulated in GBM- so the strategy in this study was to deliver miR-124 to the GBM microenvironment via extracellular vecles (EVs) as an efficient miRNA delivery vehicle as EV drugs have the unique advantage of superior potential of blood brain barrier (BBB) penetration. The NanoPhotometer® P330 was used to measure the RNA yields of the total mRNA extracted.